Treatment of advanced prostate cancer could be set to change after the early publication of significant new trial results, writes John von Radowitz.
Doctors testing the hormone drug abiraterone found that it doubled the time taken for the disease to progress in men not yet on chemotherapy.
Abiraterone is already approved as a 'last resort' treatment for prostate cancer that has stopped responding both to hormone therapies and the chemotherapy drug docetaxel.
The new findings mean that in future it could be made available to a much larger group of patients.
In the UK, 10,700 men die from the disease every year.